Business Standard

A COMMERCIAL FEATURE

What's this ?

Commercial Feature is a Business Standard Digital Marketing Initiative.

The Editorial/Content team at Business Standard has not contributed to writing or editing these articles.

For further information, please write to assist@bsmail.in

Pfizer declares lockout at Thane unit after labour unrest

The lockout may not have any impact on its business operations, as the company had made arrangements, including contract manufacturing of products and import arrangements, for the domestic market

BS B2B Bureau  |  Mumbai 

Drug manufacturer Pfizer, the marketer of brands such as Corex and Becosules, has declared a lockout at its factory in Thane (Mumbai) after unrest among workers for the past few months.The production had been stopped for at least four months, since there were “incidents of indiscipline”, making it difficult to continue operations peacefully, a Pfizer spokesperson said.
 
The plant was the only manufacturing unit of Pfizer in India employing 212 people.Pfizer said the lockout would not have any impact on its business operations, as it had a continuity plan.
 
The executive said it had made arrangements, including contract manufacturing of products and import arrangements, for the domestic market.The management has not indicated any timeline for starting operations.
 
The company said, “We are not in a position to resume operations till we are assured by the workmen the safety of our colleagues would not be compromised in any manner and the workmen will not indulge in acts of indiscipline.”
 
With an annual turnover of Rs 948 crore in India, Pfizer has a major presencein the anti-diabetes segment and is significantly present in anti-infectives, cardiovascular and respiratory drugs.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, August 05 2014. 08:08 IST
RECOMMENDED FOR YOU

Pfizer declares lockout at Thane unit after labour unrest

The lockout may not have any impact on its business operations, as the company had made arrangements, including contract manufacturing of products and import arrangements, for the domestic market

The lockout may not have any impact on its business operations, as the company had made arrangements, including contract manufacturing of products and import arrangements, for the domestic market Drug manufacturer Pfizer, the marketer of brands such as Corex and Becosules, has declared a lockout at its factory in Thane (Mumbai) after unrest among workers for the past few months.The production had been stopped for at least four months, since there were “incidents of indiscipline”, making it difficult to continue operations peacefully, a Pfizer spokesperson said.
 
The plant was the only manufacturing unit of Pfizer in India employing 212 people.Pfizer said the lockout would not have any impact on its business operations, as it had a continuity plan.
 
The executive said it had made arrangements, including contract manufacturing of products and import arrangements, for the domestic market.The management has not indicated any timeline for starting operations.
 
The company said, “We are not in a position to resume operations till we are assured by the workmen the safety of our colleagues would not be compromised in any manner and the workmen will not indulge in acts of indiscipline.”
 
With an annual turnover of Rs 948 crore in India, Pfizer has a major presencein the anti-diabetes segment and is significantly present in anti-infectives, cardiovascular and respiratory drugs.
image
Business Standard
177 22

Pfizer declares lockout at Thane unit after labour unrest

The lockout may not have any impact on its business operations, as the company had made arrangements, including contract manufacturing of products and import arrangements, for the domestic market

Drug manufacturer Pfizer, the marketer of brands such as Corex and Becosules, has declared a lockout at its factory in Thane (Mumbai) after unrest among workers for the past few months.The production had been stopped for at least four months, since there were “incidents of indiscipline”, making it difficult to continue operations peacefully, a Pfizer spokesperson said.
 
The plant was the only manufacturing unit of Pfizer in India employing 212 people.Pfizer said the lockout would not have any impact on its business operations, as it had a continuity plan.
 
The executive said it had made arrangements, including contract manufacturing of products and import arrangements, for the domestic market.The management has not indicated any timeline for starting operations.
 
The company said, “We are not in a position to resume operations till we are assured by the workmen the safety of our colleagues would not be compromised in any manner and the workmen will not indulge in acts of indiscipline.”
 
With an annual turnover of Rs 948 crore in India, Pfizer has a major presencein the anti-diabetes segment and is significantly present in anti-infectives, cardiovascular and respiratory drugs.

image
Business Standard
177 22